PD53 Glucagon-Like Peptide-1 Receptor Agonists And Polyagonists For Severe Obesity: Rapid Overview Of Outcomes Measurement
Thiago Trindade, Maria Eduarda dos Santos Puga, Flávia Tavares Silva Elias · 2025
Read PD53 Glucagon-Like Peptide-1 Receptor Agonists And Polyagonists For Severe Obesity: Rapid Overview Of Outcomes Measurement by Thiago Trindade, Maria Eduarda dos Santos Puga, Flávia Tavares Silva Elias (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768723.txt.
Description
Thiago Trindade and colleagues overview evidence on GLP-1 drugs for severe obesity. Their 2025 rapid overview supports health technology assessment planning. These drugs produce nearly twice the weight loss of older options. At least nine such drugs are approved or in late-stage testing. Clinical hopes for the class have risen sharply in recent years.
The team searched for systematic reviews with meta-analysis on severe obesity. Children-only studies and other drug classes were excluded. Reviews had to test GLP-1 agonists or polyagonists as the active treatment. The overview maps clinical outcomes reported across those reviews. Its goal is to help pick topics for a full assessment. Decision makers can see where evidence is thick or thin. The report frames a fast-moving treatment area.
Catalog record
| CREATOR | Thiago Trindade, Maria Eduarda dos Santos Puga, Flávia Tavares Silva Elias |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |